Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056476 | 0.83 | SIGMAR1 (0.47) | EPHX2EPHX1SIGMAR1POLB | |
| SCHEMBL28506963 | 0.81 | SIGMAR1 (0.46) | EPHX2EPHX1SIGMAR1POLB | |
| SCHEMBL3079393 | 0.80 | EPHX2 (0.58) | EPHX2EPHX1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL3077772 | 0.79 | SIGMAR1 (0.47) | EPHX2EPHX1SIGMAR1 | |
| SCHEMBL1497430 | 0.78 | SIGMAR1 (0.36) | EPHX2EPHX1SIGMAR1 | |
| SCHEMBL12758988 | 0.78 | TSHR (0.58) | EPHX2EPHX1SIGMAR1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL6158167 | 0.78 | EPHX2 (0.56) | EPHX2EPHX1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL6224321 | 0.77 | SIGMAR1 (0.41) | EPHX2EPHX1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL1149916 | 0.76 | EPHX2 (0.67) | EPHX2EPHX1SIGMAR1POLB | |
| SCHEMBL3069081 | 0.76 | EPHX2 (0.54) | EPHX2EPHX1SIGMAR1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9301950-B2 | Adamantane analogs | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-04-05 | — | — | US | claimed |
| US-20120270917-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-10-25 | — | — | US | claimed |
| WO-2011022191-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-02-24 | — | — | WO | claimed |
| EP-0473671-A4 | METHODS FOR TREATING ANXIETY WITH SIGMA RECEPTOR LIGANDS | — | 1992-04-01 | — | — | EP | claimed |
| EP-0473671-A1 | USE OF SIGMA-RECEPTORS LIGANDS FOR THE MANUFACTURE OF AN ANXIOLYTIC AGENT. | OREGON STATE (US) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014067-A2 | METHODS FOR TREATING ANXIETY WITH SIGMA RECEPTOR LIGANDS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1990-11-29 | — | — | WO | claimed |
| US-20230219896-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230202983-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-06-29 | — | — | US | disclosed |
| US-11155521-B2 | Cannabinoid receptor mediating compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200331861-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-10-22 | — | — | US | disclosed |
| US-10787419-B2 | Cannabinoid receptor mediating iminopyrazole compounds | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-09-29 | — | — | US | disclosed |
| US-10683270-B2 | Cannabinoid receptor mediating compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190352268-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-11-21 | — | — | US | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| US-5622968-A | ADMINISTERING TO BLOCK VOLTAGE SENSITIVE CALCIUM CHANNELS OF MAMMALIAN NEURONAL CELLS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0584088-A4 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS. | CAMBRIDGE NEUROSCIENCE RES (US) | 1995-01-18 | — | — | EP | disclosed |
| EP-0584088-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992014697-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219896-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | EPHX2 1009/4885EPHX1 1356/4885SIGMAR1 184/4885 |
| US-20230202983-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | EPHX2 1009/4885EPHX1 1356/4885SIGMAR1 184/4885 |
| US-10787419-B2 | Cannabinoid receptor mediating iminopyrazole compounds | CNR1, CNR2, GPR18 | EPHX2 1782/4885EPHX1 2117/4885SIGMAR1 286/4885 |
| US-10683270-B2 | Cannabinoid receptor mediating compounds | CNR1, CNR2, GPR18 | EPHX2 1009/4885EPHX1 1356/4885SIGMAR1 184/4885 |
| US-20190352268-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | EPHX2 1009/4885EPHX1 1356/4885SIGMAR1 184/4885 |
| US-20200331861-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | EPHX2 1009/4885EPHX1 1356/4885SIGMAR1 184/4885 |
| US-11155521-B2 | Cannabinoid receptor mediating compounds | CNR1, CNR2, GPR18 | EPHX2 1148/4885EPHX1 1404/4885SIGMAR1 189/4885 |
| US-20120270917-A1 | ADAMANTANE ANALOGS | HAVCR2, ADORA2A, ADORA1 | EPHX2 3115/4885EPHX1 2066/4885SIGMAR1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.